UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
RESPONSE ONCOLOGY, INC.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value per share
-------------------------------------------------------------------------------
(Title of Class of Securities)
761232 30 5
-------------------------------------------------------------------------------
(CUSIP Number)
December 31, 1999
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6 pages
<PAGE>
- -----------------------------------------------------------------------
CUSIP NO. 761232 30 5
- -----------------------------------------------------------------------
(1) Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (entities only)
William D. Grant
- -----------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of a Group (a) / /
(b) / /
Inapplicable
- -----------------------------------------------------------------------
(3) SEC Use Only
- -----------------------------------------------------------------------
(4) Citizenship or Place of Organization
United States
- -----------------------------------------------------------------------
(5) Sole Voting Power
753,333
Number of Shares
Beneficially -----------------------------------------------------
Owned by (6) Shared Voting Power
Each 317,194
Reporting
Person -----------------------------------------------------
With: (7) Sole Dispositive Power
753,333
-----------------------------------------------------
(8) Shared Dispositive Power
317,194
- -----------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned By Each Reporting Person
1,070,527
- -----------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
/ /
Page 2 of 6 pages
<PAGE>
- -----------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
8.6%
- -----------------------------------------------------------------------
(12) Type of Reporting Person
IN
- -----------------------------------------------------------------------
Page 3 of 6 pages
<PAGE>
ITEM 1.
(a) Name of Issuer:
Response Oncology, Inc.
(b) Address of Issuer's Principal Executive Offices:
1775 Moriah Woods Boulevard
Memphis, Tennessee 38117
ITEM 2.
(a) Name of Person Filing:
William D. Grant
(b) Address of Principal Business Office or, if none, Residence:
One Ward Parkway
Suite 130
Kansas City, MO 64112
(c) Citizenship:
United States
(d) Title of Class of Securities:
Common Stock, $0.01 par value per share
(e) CUSIP Number:
761232 30 5
ITEM 3. If this statement is filed pursuant to Sections 240.13d-1(b),
or 240.13d-2(b) or (c), check whether the person
filing is a:
Not applicable.
Page 4 of 6 pages
<PAGE>
ITEM 4. Ownership.
(a) Amount Beneficially Owned: 1,070,527 shares.
The amount of shares reported as beneficially owned
includes: (i) 168,637 shares held by three family trusts, for
which the reporting person acts as co-trustee with UMB Bank,
N.A., Kansas City, Missouri, and in that capacity shares
voting and investment powers; (ii) 86,935 shares held by two
family trusts, as to which the reporting person has the right
to direct the voting and disposition of such shares, and
therefore shares voting and investment powers with the
trustee, UMB Bank, N.A.; (iii) 25,629 shares held by a trust
for the benefit of a niece, for which the reporting person
acts as co-trustee with UMB Bank, N.A., and in that capacity
shares voting and investment powers, as to which shares the
reporting person disclaims beneficial ownership; and (iv)
35,993 shares owned by the reporting person's wife, as to
which shares the reporting person disclaims beneficial
ownership.
(b) Percent of Class: 8.6%
(c) Number of shares as to which the person has:
(i) sole power to vote or to direct the vote: 753,333
(ii) shared power to vote or to direct the vote: 317,194
(iii) sole power to dispose or to direct the disposition of:
753,333
(iv) shared power to dispose or to direct the disposition of:
317,194
ITEM 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Page 5 of 6 pages
<PAGE>
ITEM 6. Ownership of More Than Five Percent on Behalf of Another Person.
Each trust described in Item 4(a) hereof has the right to receive and
the power to direct the receipt of dividends from, or the proceeds
from the sale of, shares of Common Stock of the Issuer held by such
trust.
Other persons have the right to receive dividends on 237,090 shares of
the securities listed in item 4(a).
ITEM 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company.
Not applicable.
ITEM 8. Identification and Classification of Members of the Group.
Not applicable.
ITEM 9. Notice of Dissolution of Group.
Not applicable.
ITEM 10. Certification.
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired
and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the
securities and were not acquired and are not held in
connection with or as a participant in any transaction having
that purpose or effect.
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
/s/ W.D. Grant
----------------------------
W.D. Grant
Dated: February 4, 2000
page 6 of 6 pages
